Researchers Need Your Help to Study Potential COVID-19 Treatments
Research Center: University of Massachusetts Medical School
Location: 55 N Lake Ave, Worcester, MA 01655, United States
Lead Researcher: Robert Finberg, MD
IRB Committee: This study has been reviewed and approved by the Advarra Institutional Review Board
About the Study
Tested positive for COVID-19 and looking for ways to treat your symptoms? As of today, there are no proven treatments to help those who have COVID-19. Since the virus can quickly spread through contact with others, it’s important to manage symptoms early to avoid being hospitalized or putting others at risk.
This research study aims to evaluate new therapies for COVID-19. These therapies may help people manage their symptoms early and prevent possible complications and hospitalization. The results of this study may not only prevent and treat COVID-19, but may also help society by expanding the understanding of similar conditions and prevention.
- Participants will receive a new potential treatment for COVID-19 at no cost.
- Participants may experience improvements to their COVID-19 symptoms.
- Participants will be contributing valuable information that may help researchers find solutions to end the global pandemic.
- Participants will be compensated up to $375 for participating in this study. Compensation will only be provided to eligible participants for each visit they complete.
- Participants will be contributing to a cause that will help people all over the world.
- If you decide to participate in the study and later feel that you no longer wish to be part of it, you can withdraw at any time.
- Any information that you provide will be kept strictly confidential, except as required by law.
- Qualified health professionals will monitor your health as it relates to the study.
Who Can Participate?
- Men and women aged 18 and above who have tested positive for COVID-19 within the last 10 days.
- Must be experiencing at least one of the following COVID-19 symptoms in the last 24 hours:
- stuffy or runny nose
- sore throat
- shortness of breath
- low energy or tiredness
- muscle or body aches
- chills or shivering
- feeling feverish or having fever (temperature reading of 37.2°C or higher)
- changes in the sense of taste or smell
- Must not have any medical conditions requiring surgery within the last 7 days
- Must be able to attend up to 2-6 study visits at the research site over approximately 6 to 18 months
Key Study Details
The study team can explain the research study in its entirety but some study details are:
- While this study will investigate different COVID-19 medications, participants will only be receiving 1 type of medication throughout the study.
- Participants will either be receiving an infusion or 4 injections depending on the treatment arm they are randomized to.
- Participants will be monitored in the clinic for two hours after they receive the infusions or injections.
- Participants will be asked to keep a study diary and maintain a daily record of their symptoms.
- Participants will receive daily reminders through text, telephone, or email that will help them remember to complete their study diaries.
- Participants will be asked to have swab tests to detect the presence of the COVID-19 virus.
- Swab tests will either be self-collected or collected by the study staff.
- Participants will be asked to have their blood drawn.
About the Research Center:
University of Massachusetts Medical School
The University of Massachusetts is a world-class public research university committed to advancing knowledge and transforming lives. Through its world-class educational programs, groundbreaking research enterprise, and its impactful community service and industry engagement activities, UMass harnesses the revolutionary spirit of Massachusetts to deliver an unparalleled student experience.
Due to the current situation with the COVID-19 pandemic, the researchers would like to assure the participants that ensuring the safety of the participants as well as the study staff is of utmost importance.